Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.45 |
| ▸ | KDM5C | P41229 | 7/20 | 0.45 |
| ▸ | KDM4A | O75164 | 7/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545205 | 0.80 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1759894 | 0.79 | KDM4C (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25933765 | 0.77 | KDM4C (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25709497 | 0.76 | KDM4C (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21378747 | 0.74 | CYP1A2 (0.55) | KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL15745601 | 0.74 | CYP1A2 (0.55) | KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21378793 | 0.74 | CYP1A2 (0.55) | KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23583774 | 0.73 | KDM4C (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30007857 | 0.73 | KDM4E (0.50) | KDM4EKDM5AALDH1A1MAPTCYP1A2 | |
| SCHEMBL4000772 | 0.73 | KDM4E (0.50) | KDM4EKDM5AALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070015815-A1 | Hydrazide substrate shuts down protein biosynthesis capability in cells that host a metastatic or malignant disease mechanism | DELOACH REUBEN E | 2007-01-18 | — | — | US | disclosed |
| EP-1581222-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1268217-A2 | CONTROL OF VOLATILE CARBONYL COMPOUND IN COMPOSITIONS USED IN PRINTING, PRINTING METHODS AND RESULTING PRINTED STRUCTURE | Cellresin Technologies, LLC (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001069322-A2 | CONTROL OF VOLATILE CARBONYL COMPOUND IN COMPOSITIONS USED IN PRINTING, PRINTING METHODS AND RESULTING PRINTED STRUCTURE | CELLRESIN TECHNOLOGIES, LLC (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | GABRP 3958/4885GABRD 3011/4885GABRA1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.